Monitoring Guidelines for Immunomodulatory Drug Therapy: Systemic Steroids

The presentation focuses on the monitoring guidelines for systemic steroid therapy, highlighting the risks, benefits, and complications associated with corticosteroids. It discusses the various types of synthetic corticosteroids, their mineral corticoid effects, and variations in biological half-lives, emphasizing the swift therapeutic action of these medications in managing inflammatory diseases. Key points include the importance of careful monitoring for side effects, specifically osteoporosis, adrenal insufficiency, and metabolic changes such as hypertension and hyperglycemia. The new 2022 guidelines from the American College of Rheumatology for glucocorticoid-induced osteoporosis suggest initiating calcium and vitamin D supplementation for patients on steroids for more than three months and the necessity of DEXA scans for assessing bone health. Special considerations for patient regimens vary based on individual needs, including dosing strategies and the potential for drug interactions. Gastrointestinal prophylaxis with proton pump inhibitors is recommended for patients at higher risk of ulcers, especially those on combined steroid and NSAID therapy. Additionally, prophylaxis for pneumocystis pneumonia (PCP) is indicated for patients on high-dose corticosteroids, particularly in the context of other immunosuppressive therapies. A case study illustrates the application of these guidelines in managing a patient with dermatomyositis, underscoring the need for comprehensive care through bone health assessment, GI protection, and infection prophylaxis. Overall, the presentation emphasizes the necessity of individualized, proactive management in patients receiving steroid therapy.